New drug shows promise for tough blood cancers in early trial
NCT ID NCT05526313
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 31 times
Summary
This early-phase study tested a new drug called Purinostat Mesylate in 29 people with blood cancers like lymphoma and leukemia that had returned or stopped responding to standard treatments. The goal was to check the drug's safety, find the best dose, and see how the body processes it. The drug works by blocking certain proteins that help cancer cells grow, and early results suggest it may be safe and effective enough to study further.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
West China Hospital Sichuan University
Chengdu, Sichuan, 610000, China
Conditions
Explore the condition pages connected to this study.